Clinical Trial Update: Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting results for bevacizumab in combination with metronomic temozolomide in recurrent malignant glioma, including glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Malignant Glioma

Drugs mentioned

• Avastin (bevacizumab)
• Temodar (Temozolomide)

Snippet

Sponsor: Duke University | Conditions: Glioblastoma Multiforme | Phase 2 | Status: COMPLETED | Results posted: 2013-04-22